ImmuSAFE Biochip

ABOUT THE lmmuSAFE™ BIOCHIP

lmmuSAFE™ is a novel, lab-based biochip test for COVID-19 that enables highly quantitative determination of both the level and target location of SARS-CoV-2 antibodies in an individual. The test answers 4 fundamental questions:

ImmuSAFE COVID19 Test Biochip Kit | Sengenics Proteomics | Krex Protein Microarrays

Scenario 1 - suspected COVID-19 positive individual

1. Confirming with high accuracy whether an individual has been infected with the virus that causes COVID-19.
2. Determining whether the level and target location of the antibodies in an individual are likely to offer protectivity.

ImmuSAFE COVID19 Test Biochip Kit | Sengenics Proteomics | Krex Protein Microarrays

Scenario 2 - following COVID-19 vaccination

3. Confirming that an individual has generated a sufficiently strong immune response to the vaccine to confer protection.
4. Retesting to confirm the status of ongoing protection and evaluating whether a booster vaccine is required.

lmmuSAFE™ utilises Sengenics’ patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites. Multiple domains of SARS-CoV-2 Nucleocapsid and Spike proteins including both full-length and numerous truncated versions are used in the tests.

The biochip enables the determination of the target epitopes, titres and immunoglobulin class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination. lmmuSAFE™ can also enable quantitative assessment of patient response in vaccination trials, including differentiation of whether observed antibody responses are due directly to the vaccine or to prior SARS-CoV-2 exposure.

Key Applications

ImmuSAFE™ can be utilised for vaccine clinical trials or sero-prevalence research studies. 

Population antibody profiling for sero-prevalence research

The target epitope of antibodies produced following infection exhibit a significant level of diversity across a population. ImmuSAFE™ provides a more accurate determination of sero-prevalence by targeting multiple domains of SARS-CoV-2 proteins.

Determine the protective quality and quantity of antibodies produced

Some individuals produce antibodies that target locations which are neutralising (protective), whereas others produce non-neutralising antibodies. ImmuSAFE™ can be used to identify individuals who have high titres of potentially neutralising antibodies against SARS-CoV-2.

Enable quantitative assessment of antigen-specific response by individuals in vaccine trials

Investigate SARS-CoV-2 specific immunoreactivity in patients and healthy individuals for vaccine development, safety and efficacy determination in clinical trials.

As shown below, data from the ImmuSAFE™ test enables 3 major conclusions to be inferred:

  1. There is a wide variation in antibody titres across SARS-CoV-2 infected individuals
  2. There is a high degree of variation in patient-specific antibody responses to the different domains of SARS-CoV-2 proteins
  3. Wider coverage of target epitopes leads to increased sensitivity and specificity
ImmuSAFE COVID19 Test Biochip Kit | Sengenics Proteomics | Krex Protein Microarrays

Relative IgG titres in convalescent COVID-19 patient and healthy sera against different domains of SARS-CoV-2 nucleocapsid [For illustration purposes only].

Product Description

The ImmuSAFE™ product range also includes other biochip-based tests that incorporate additional viral antigens. Content can be customised based on individualised requirements for vaccine clinical trials or sero-prevalence research studies.

CodeProduct Description
39508HImmuSAFE™ COVID+ Protein Microarray
contains multiple SARS-CoV-2 specific domains (Nucleocapsid and Spike proteins) including full-length and numerous truncated versions and INF, TNF, ANA etc. Key applications are vaccine clinical trials and sero-prevalence research studies.

FEATURED PRODUCTS

High-throughput autoantibody profiling against 1600+ proteins

Quantification of autoantibodies to 200+ clinically relevant CT antigens

Simultaneous screening of 100+
wild-type and mutant p53

Multi-antigen, multi-domain
COVID-19 antibody test

Sengenics - Functional Proteomics | Krex Technology | Protein Microarray Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389